Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Fallopian Tube Neoplasms 16Ovarian Neoplasms 14Triple Negative Breast Neoplasms 9Lung Neoplasms 9Brenner Tumor 9Breast Neoplasms, Male 9Adenocarcinoma of Lung 9Adenocarcinoma, Bronchiolo-Alveolar 8Unspecified Adult Solid Tumor, Protocol Specific 7Endometrial Neoplasms 7Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 6Melanoma 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Esophageal Neoplasms 3Carcinoma, Transitional Cell 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2Platinum-Refractory Fallopian Tube Carcinoma 2Oropharyngeal Neoplasms 2Endometrial Adenocarcinoma 2Carcinoma 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Testicular Neoplasms 1Stomach Neoplasms 1

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Advanced NUT Carcinoma × Taxes × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡